ClinConnect ClinConnect Logo
Search / Trial NCT05704582

RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders

Launched by CIUSSS DE L'EST DE L'ÎLE DE MONTRÉAL · Jan 20, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Cannabis Virtual Reality Intervention Psychotic Disorders Substance Use Disorders

ClinConnect Summary

This clinical trial is studying a new treatment called the Avatar Intervention to see if it can help people with psychotic disorders reduce their cannabis use more effectively than traditional supportive counseling. The trial is open to adults aged 18 and older who have been diagnosed with cannabis use disorder and have conditions like schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Participants will be selected based on specific criteria to ensure they are suitable for the study.

If you or someone you know is eligible and decides to participate, you can expect to receive either the Avatar Intervention or supportive counseling. Throughout the trial, researchers will monitor your progress and help you manage your cannabis use. It's important to note that individuals with other substance use disorders, ongoing treatments for cannabis use, or certain health conditions will not be eligible to join. The trial is currently recruiting participants, and your involvement could contribute to finding better ways to support people with these challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Males or females over 18 years of age who meet the DSM-5 criteria for CUD (≥4 criteria) ;
  • Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Diagnoses will be established with the Structured Interview for DSM-5 (SCID-5).
  • Exclusion Criteria:
  • Current SUD for a substance other than cannabis ;
  • Ongoing pharmacological or psychological treatment for CUD ;
  • Ongoing detoxification for cannabis withdrawal ;
  • Presence of neurological disorders ;
  • Presence of a severe and unstable physical illness ;
  • Inability to provide consent.

About Ciusss De L'est De L'île De Montréal

Ciusss de l'Est de l'Île de Montréal is a leading healthcare organization dedicated to enhancing the health and well-being of the communities it serves. As a prominent clinical trial sponsor, Ciusss de l'Est conducts innovative research aimed at advancing medical knowledge and improving patient outcomes. With a focus on collaboration and ethical standards, the organization fosters a multidisciplinary approach to clinical research, ensuring rigorous methodologies and comprehensive patient care. Through its commitment to scientific excellence and community health, Ciusss de l'Est plays a vital role in shaping the future of healthcare in the region.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Alexandre Dumais, MD, PhD

Principal Investigator

University of Montreal, Institut universitaire en santé mentale de Montréal

Stephane Potvin, PhD

Principal Investigator

University of Montreal, Institut universitaire en santé mentale de Montréal

Emmanuel Stip, MD, MSc

Study Chair

United Arab Emirates University

Amal Abdel Baki, MD, MSc

Study Chair

University of Montreal, Centre hospitalier de l'Université de Montréal

Robert-Paul Juster, PhD

Study Chair

University of Montreal, Institut universitaire en santé mentale de Montréal

Marie-Hélène Goulet, PhD

Study Chair

University of Montreal, Institut universitaire en santé mentale de Montréal

Luigi De Benedictis, MD

Study Chair

Institut universitaire en santé mentale de Montréal

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials